Glipizide 5mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Glipizide

Available from:

Viatris UK Healthcare Ltd

ATC code:

A10BB07

INN (International Name):

Glipizide

Dosage:

5mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 06010201; GTIN: 5016695330013 5016695002804

Patient Information leaflet

No. of colours
Colours
Non-Print
Colours
Date:
Time:
Equate CMYK
with
Description
Component Type
Affiliate Item Code
Superceded Affiliate Item Code
TrackWise PR No.
MA No.
Packing Site/Printer
Supplier Code
Sign-offs
Pharma Code
SAP No.
Vendor Job No.
Proof No.
Client Market
Keyline/Drawing No.
Barcode Info
Dimensions
Main Font
Body Text Size
Page Count
03 Dec 2014
1/2
11:12
Glipizide 5mg 56
Leaflet
521715
316069
521715
04569/0308
N/A
LT1324AH
TBC
N/A
242271
1
UK
N/A
N/A
1
Black
Myriad Pro
8 pt
170 x 240mm
1211122
1211122
TBC
TBC
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
GLIPIZIDE 5 MG TABLETS
(glipizide)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR
YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor
or pharmacist.
•
This medicine has been prescribed for you only. Do not
pass it on to others. It may harm them, even if their signs of
illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist.
This includes any possible side effects not listed in this
leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Glipizide is and what it is used for
2.
What you need to know before you take Glipizide
3.
How to take Glipizide
4.
Possible side effects
5.
How to store Glipizide
6.
Contents of the pack and other information
1. WHAT GLIPIZIDE IS AND WHAT IT IS USED FOR
Glipizide is one of a group of medicines called sulfonylureas.
Glipizide is used to reduce blood sugar levels (antidiabetic
medicine taken by mouth).
Glipizide is used in a certain form of diabetes (type 2 diabetes
mellitus), when diet, exercise and weight loss alone do not have
an adequate effect.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE GLIPIZIDE
DO NOT TAKE GLIPIZIDE IF YOU:
•
are allergic to glipizide, other sulfonylureas or any of the other
ingredients of this medicine (listed in section 6)
•
suffer from kidney or liver disease
•
suffer from thyroid problems
•
have insulin-

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Glipizide 5 mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains glipizide 5 mg
Excipient with known effect
Each tablet contains 152 mg lactose monohydrate
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet
White oval biconvex uncoated tablets. Tablets are identified by
‘GP’, a breakline and ‘5’ on
one side and ‘G’ on the reverse.
The tablet can be divided into equal doses.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Glipizide is indicated in the control of blood glucose levels in
addition to the control
of diet for patients with non insulin dependent diabetes mellitus
(Type II NIDDM),
when hyperglycaemia cannot be controlled by diet alone and advice has
been given
on weight reduction and exercise.
Stable patients with non insulin dependent diabetes mellitus not
controlled by
regulation of their diet alone are likely to be controlled by
glipizide.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
As for any hypoglycaemic agent, dosage must be adapted for each
individual case.
Short term administration of glipizide may be sufficient during
periods of transient
loss of control in patients usually controlled well on diet.
Initial dose
The recommended starting dose is 5 mg, given before breakfast or the
midday meal.
Mild diabetics, elderly or those with liver disease may be started on
2.5 mg.
Titration
Dosage adjustments should ordinarily be in increments of 2.5 mg or 5
mg, as
determined by blood glucose response. At least several days should
elapse between
titration steps. The maximum recommended single dose is 15 mg. If this
is not
sufficient, splitting the daily dosage may prove effective. Doses
above 15 mg should
ordinarily be divided.
Maintenance
Some patients may be effectively controlled on a once-a-day regimen.
Total daily
dosages above 15 mg should ordinarily be divided.
The maximum recommended daily dosage is 20 mg.
Paediatric population
Safety and effectiveness in childre